Linkage of aerobic glycolysis to sodium-potassium transport in rat skeletal muscle. Implications for increased muscle lactate production in sepsis.
Although a linkage between aerobic glycolysis and sodium-potassium transport has been demonstrated in diaphragm, vascular smooth muscle, and other cells, it is not known whether this linkage occurs in skeletal muscle generally. Metabolism of intact hind-leg muscles from young rats was studied in vitro under aerobic incubation conditions. When sodium influx into rat extensor digitorum longus (EDL) and soleus muscles was facilitated by the sodium ionophore monensin, muscle weight gain and production of lactate and alanine were markedly stimulated in a dose-dependent manner. Although lactate production rose in both muscles, it was more pronounced in EDL than in soleus. Monensin-induced lactate production was inhibited by ouabain or by incubation in sodium-free medium. Preincubation in potassium-free medium followed by potassium re-addition also stimulated ouabain-inhibitable lactate release. Replacement of glucose in the incubation medium with pyruvate abolished monensin-induced lactate production but exacerbated monensin-induced weight gain. Muscles from septic or endotoxin-treated rats exhibited an increased rate of lactate production in vitro that was partially inhibited by ouabain. Increases muscle lactate production in sepsis may reflect linked increases in activity of the Na+, K+-ATPase, consumption of ATP and stimulation of aerobic glycolysis.
James
J H
JH
Department of Surgery, University of Cincinnati, Ohio 45267, USA.
Fang
C H
CH
Schrantz
S J
SJ
Hasselgren
P O
PO
Paul
R J
RJ
Fischer
J E
JE
D000332:Aerobiosis; D000409:Alanine / Q000378:metabolism; D000596:Amino Acids / Q000032:analysis; D000818:Animals; D004305:Dose-Response Relationship, Drug; D005947:Glucose / Q000494:pharmacology; D018698:Glutamic Acid / Q000378:metabolism; D006019:Glycolysis; D006614:Hindlimb / Q000378:metabolism; D006863:Hydrogen-Ion Concentration; D019344:Lactic Acid / Q000037:antagonists & inhibitors / Q000378:metabolism*; D008070:Lipopolysaccharides / Q000494:pharmacology; D008297:Male; D008985:Monensin / Q000494:pharmacology; D018482:Muscle, Skeletal / Q000378:metabolism*; D010042:Ouabain / Q000494:pharmacology; D011188:Potassium / Q000494:pharmacology; D019289:Pyruvic Acid / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012772:Shock, Septic / Q000378:metabolism*; D012964:Sodium / Q000494:pharmacology; D000254:Sodium-Potassium-Exchanging ATPase / Q000378:metabolism*
D000596:Amino Acids; D008070:Lipopolysaccharides; D019344:Lactic Acid; D018698:Glutamic Acid; D010042:Ouabain; D019289:Pyruvic Acid; D008985:Monensin; D012964:Sodium; D000254:Sodium-Potassium-Exchanging ATPase; D005947:Glucose; D000409:Alanine; D011188:Potassium